Compare AVB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVB | BIIB |
|---|---|---|
| Founded | 1978 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8B | 24.2B |
| IPO Year | 1994 | 1991 |
| Metric | AVB | BIIB |
|---|---|---|
| Price | $175.99 | $195.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 26 |
| Target Price | ★ $202.84 | $195.13 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 02-04-2026 | 02-06-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 7.40 | ★ 8.79 |
| Revenue | $3,041,189,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $4.43 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $23.81 | ★ $22.36 |
| Revenue Growth | ★ 2.59 | 2.22 |
| 52 Week Low | $166.73 | $110.04 |
| 52 Week High | $230.21 | $202.41 |
| Indicator | AVB | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 64.38 |
| Support Level | $173.75 | $187.20 |
| Resistance Level | $181.18 | $202.41 |
| Average True Range (ATR) | 4.72 | 6.19 |
| MACD | 0.29 | 1.76 |
| Stochastic Oscillator | 58.69 | 81.34 |
AvalonBay Communities owns a portfolio of 295 apartment communities with almost 90,000 units and is developing 20 additional properties with approximately 7,300 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).